Write in a clean editor, then format for Transplantation Reviews in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Transplantation Reviews is a peer-reviewed journal published by Elsevier, covering Renal Transplantation Outcomes and Treatments, Organ Transplantation Techniques and Outcomes, Transplantation: Methods and Outcomes.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Transplantation Reviews 12 (2023) 45–58.
Formats any DOI in Transplantation Reviews style. No sign-up. |
| Publishes research in | Renal Transplantation Outcomes and Treatments Organ Transplantation Techniques and Outcomes Transplantation: Methods and Outcomes Diverse Scientific and Economic Studies Organ Donation and Transplantation |
| ISSN | 0955-470X |
| Citation impact (2-yr) | 3.02 |
| h-index | 66 |
| i10-index | 561 |
| Total citations | 23,053 |
| Article processing charge | $3,450 |
| Top institutions publishing here | University of Wisconsin–Madison |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Organ donation and transplantation remain the best and most cost-effective clinical solution for end-stage organ failure. Several agencies across the US and Europe provide legislative, regulatory, and humanitarian services to generate smoother applications in all transplantation processes and donor-recipient relationships. US and European statistics present nine types of grafts, with kidneys being the most transplanted…
Mammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive agents in solid-organ transplant recipients (everolimus and sirolimus) and as antineoplastic therapies for various cancers (eg, advanced renal cell carcinoma; everolimus, temsirolimus, ridaforolimus). Relevant literature, obtained from specific PubMed searches, was reviewed to evaluate the incidence and mechanistic features of specific adverse events (AEs)…
